This bill terminates certain limitations regarding drug rebates under Medicaid. Currently, the maximum rebate that drug manufacturers must pay under Medicaid for single-source and innovator multiple-source drugs is 100% of the average manufacturer price of the drug. The bill specifies that this limitation only applies to rebate periods that begin before January 1, 2020.